(19)
(11) EP 3 328 426 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.06.2021 Bulletin 2021/22

(45) Mention of the grant of the patent:
07.04.2021 Bulletin 2021/14

(21) Application number: 16753597.0

(22) Date of filing: 27.07.2016
(51) International Patent Classification (IPC): 
A61K 45/06(2006.01)
A61K 31/517(2006.01)
A61P 35/00(2006.01)
A61K 33/243(2019.01)
G01N 33/574(2006.01)
C07K 16/32(2006.01)
 A61K 31/337(2006.01)
A61K 33/24(2019.01)
A61K 31/7068(2006.01)
C12Q 1/6886(2018.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/EP2016/067892
(87) International publication number:
WO 2017/017133 (02.02.2017 Gazette 2017/05)

(54)

TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

BEHANDLUNG VON PATIENTEN MIT DIAGNOSTIZIERTEM DUKTALEN ADENOKARZINOM DES PANKREAS MIT MONOKLONALEN ANTIKÖRPERN GEGEN DEN EPIDERMALEN WACHSTUMSFAKTOR REZEPTOR (EGFR)

TRAITEMENT DES PATIENTS DIAGNOSTIQUÉS AVEC UN ADÉNOCARCINOME CANALAIRE PAR DES ANTICORPS MONOCLONAUX CONTRE LE RECEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 27.07.2015 EP 15178489

(43) Date of publication of application:
06.06.2018 Bulletin 2018/23

(73) Proprietors:
  • InnoCIMAb Pte Ltd
    Singapore 659065 (SG)
  • Oncoscience AG
    22880 Wedel (DE)

(72) Inventors:
  • STRUMBERG, Dirk
    44621 Herne (DE)
  • SCHULTHEIS, Beate
    Herne (DE)
  • EBERT, Matthias, P.
    Munich (DE)
  • SIVEKE, Jens
    Munich (DE)
  • KERKHOFF, Andrea
    Muenster (DE)
  • HOFHEINZ, Ralf
    Mannheim (DE)
  • BEHRINGER, Dirk, M.
    Bochum (DE)
  • SCHMIDT, Wolfgang, E.
    Bochum (DE)
  • GOKER, Erdem
    Izmir (TR)
  • DE DOSSO, Sara
    Bellinzona (CH)
  • KNEBA, Michael
    Kiel (DE)
  • YALCIN, Suayib
    Ankara (TR)
  • OVERKAMP, Friedrich
    Recklinghausen (DE)
  • SCHLEGEL, Frank
    Eschweiler (DE)
  • DOMMACH, Markus
    Duesseldorf (DE)
  • ROHRBERG, Robert
    Halle (DE)
  • STEINMETZ, Tilman
    Cologne (DE)
  • BACH, Ferdinand
    22880 Wedel (DE)
  • REUTER, Dirk
    22880 Wedel (DE)
  • ILYAS, Rikrik, Asiyah
    Singapore 658065 (SG)
  • IZNAGA ESCOBAR, Normando, E.
    Singapore 658065 (SG)

(74) Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)


(56) References cited: : 
EP-A1- 2 070 547
WO-A1-2014/095766
 WO-A1-2013/138371
   
  • Sideways: "EGFR inhibition is effective against KRAS-wild-type disease | Nature Reviews Clinical Oncology", Nature reviews clinical oncology, 25 July 2017 (2017-07-25), XP55536776, Retrieved from the Internet: URL:https://www.nature.com/articles/nrclin onc.2017.119 [retrieved on 2018-12-19]
  • B. SCHULTHEIS ET AL: "Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study", ANNALS OF ONCOLOGY., vol. 28, no. 10, 6 July 2017 (2017-07-06), pages 2429-2435, XP055652203, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdx343
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).